# Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

> **NCT01954784** · PHASE1 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** fludarabine phosphate
- **RADIATION:** total-body irradiation
- **PROCEDURE:** nonmyeloablative allogeneic hematopoietic stem cell transplantation
- **DRUG:** cyclosporine
- **DRUG:** mycophenolate mofetil
- **DRUG:** bortezomib
- **DRUG:** lenalidomide
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01954784
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10-07
- **Primary completion:** 2017-01-30
- **Final completion:** 2017-01-30
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Funding unavailable
- **Last updated:** 2017-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01954784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01954784, "Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01954784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*